OliX Pharmaceuticals, Inc (KOSDAQ: 226950)

Market Cap	284.26B
Revenue (ttm)	16.14B
Net Income (ttm)	-25.30B
Shares Out	17.24M
EPS (ttm)	-1,534.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	682,330
Open	18,680
Previous Close	18,550
Day's Range	16,320 - 18,710
52-Week Range	8,280 - 32,750
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 19, 2025

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 72
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226950

Financial Performance

In 2023, OliX Pharmaceuticals's revenue was 17.06 billion, an increase of 83.09% compared to the previous year's 9.32 billion. Losses were -19.10 billion, -2.02% less than in 2022.